Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease

The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment

Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology

Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types

Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges  

However, the future of TKI combinations for these rare tumours is uncertain

New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population 

Several studies report on promising data with immunomodulation and alternative approaches

However, presented findings raise some questions about their efficacy in non-injected lesions and the durability of responses